Results 211 to 220 of about 621,850 (267)

Gut‐microbiota‐brain Axis and post‐traumatic epilepsy

Epilepsia Open, EarlyView.
Abstract There has been growing evidence that perturbations in gut‐microbiota‐brain axis (GMBA) are involved in mechanisms of chronic sequelae of traumatic brain injury (TBI). This review discusses the connection between GMBA and post‐traumatic epilepsy (PTE), the latter being a common outcome of TBI.
Andrey Mazarati
wiley   +1 more source

Editorial: Gut microbiome-driven pathogenesis and intervention strategies in liver diseases. [PDF]

Front Med (Lausanne)
Xiang Z, Chen Y, Ji R, Wei X, Xu X.
europepmc   +1 more source

Intestinal microbiome alterations in pediatric epilepsy: Implications for seizures and therapeutic approaches

Epilepsia Open, EarlyView.
Abstract The intestinal microbiome plays a pivotal role in maintaining host health through its involvement in gastrointestinal, immune, and central nervous system (CNS) functions. Recent evidence underscores the bidirectional communication between the microbiota, the gut, and the brain and the impact of this axis on neurological diseases, including ...
Teresa Ravizza, Greta Volpedo, Antonella Riva, Pasquale Striano, Annamaria Vezzani   +4 more
wiley   +1 more source

Connecting gut microbiome composition to symptom severity and host genetics in endometriosis. [PDF]

Front Microbiol
Nardone GG, Rosso LE, Santin A, Spedicati B, Cappellani S, Concas MP, Zito G, Romano F, Di Lorenzo G, Zanotta N, Campisciano G, Ricci G, Comar M, Girotto G.   +13 more
europepmc   +1 more source

Ketogenic diet for infantile epileptic spasms

Epilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury, Anamika Choudhary, Andy Cheuk‐Him Ng, Cezar Gavrilovici   +3 more
wiley   +1 more source

Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis. [PDF]

Liver Int
Liu J, Garcia-Guevara F, Macnaughtan J, Jin Y, Ferret-Miñana A, Clasen F, Yuen N, Maset RG, Ramón-Azcón J, Kerbert AJC, Portlock T, Martinez J, Habtesion A, Phillips A, De Chiara F, Ingavle G, Baldwin T, Jimenez C, Zaccherini G, Husi K, Rodriguez-Gandia M, Cordero-Sanchez P, Soeda J, Oben JA, Church K, Li JV, Jalan A, Juanola A, Sola E, Eaton S, Morgan C, Avery T, Kowalski M, Green D, Gander A, Edwards LA, Cox IJ, Cortez-Pinto H, Wiest R, Durand F, Caraceni P, Elosua R, Vila J, Pavesi M, Arroyo V, Davies N, Mookerjee RP, Sandeman S, Mehta G, Marchesi JR, Albillos A, Rohn JL, Andreola F, Shoaie S, Jalan R.   +54 more
europepmc   +1 more source

The gut microbiome and drug‐resistant epilepsy: Microbiome–antiseizure medication interactions and implications for pharmacoresistance

Epilepsia Open, EarlyView.
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar, Majd A. AbuAlrob, Musab Ali, Simona Lattanzi, Boulenouar Mesraoua   +4 more
wiley   +1 more source